Can compounding pharmacies make BPC-157 now?

The July 2026 advisory vote did not by itself create immediate compounding authority. The FDA still has to act. Patients should wait for final FDA action and should not treat "research use only" sellers as pharmacies.

Why the vote did not change access

The regulatory direction changed; patient access did not. A positive advisory recommendation is a step toward possible inclusion on the 503A Bulks List, but the FDA must still complete its review and take formal action. That process can take months or longer, and the agency is not required to follow the committee.

Until the FDA acts, the legal and practical status does not change merely because the committee voted.

What a lawful pathway would look like

If the FDA ultimately adds a peptide to the list, a licensed U.S. pharmacy could have a clearer legal path to prepare it for an individual patient with a prescription. That would bring a real prescriber-patient relationship, screening for risks and interactions, pharmacy labeling and dosing instructions, accountable sourcing and handling, and a route for reporting product-quality problems and adverse events.

Even then, medications compounded with those ingredients would remain compounded drugs. Compounded drugs are not FDA-approved, and the FDA does not review each compounded product for safety, effectiveness, or quality before it is dispensed.

A warning about "research use only" sellers

A product labeled "research use only" or "not for human consumption" is outside the prescription-drug supply chain. Its identity, strength, sterility, and suitability for human use should not be assumed, and a polished website or a seller-posted lab report does not turn it into a prescription medication.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.